Several major US and international organizations focused on combating HIV and AIDS announced a new initiative on Tuesday to quickly make a potentially “game-changing” HIV prevention drug accessible in lower-income countries. The Global Fund, an international partnership fighting AIDS, tuberculosis, and malaria, has teamed up with PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) to ensure affordable and equitable access to lenacapavir, a twice-yearly injectable treatment for HIV pre-exposure prophylaxis (PrEP).
Lenacapavir, which is administered biannually, is seen as a promising breakthrough in HIV prevention. The collaboration aims to provide this medication to high-risk populations in resource-limited settings, offering a new tool in the fight against HIV/AIDS. This partnership represents a significant step toward enhancing access to effective HIV prevention methods in regions with the greatest need.
There is growing optimism that lenacapavir, an antiretroviral drug already approved in several countries for treating adults with multidrug-resistant HIV, could significantly accelerate the global fight against the virus. Early trials have shown the drug to be 100% effective in preventing HIV infection.
“If rolled out at scale alongside other HIV prevention methods, lenacapavir has the potential to accelerate progress toward ending the HIV/AIDS public health threat and ensuring a sustainable response to HIV beyond 2030,” a statement emphasized.
The Global Fund has outlined a goal to secure sustainable mechanisms for countries to access this groundbreaking HIV prevention tool. The initiative aims to provide lenacapavir to at least two million people over the next three years, ensuring widespread access to this potentially transformative treatment.
The initiative, supported by the World Health Organization (WHO), the Children’s Investment Fund Foundation, and the Bill & Melinda Gates Foundation, is contingent on receiving regulatory approvals and a formal recommendation from the WHO.
In October, US pharmaceutical company Gilead announced it had signed royalty-free voluntary licensing agreements with six generic drugmakers, enabling them to produce low-cost versions of lenacapavir for HIV prevention in 120 lower-income countries.
Peter Sands, the head of the Global Fund, emphasized that the goal is to collaborate with Gilead and the manufacturers involved in the licensing agreements to expedite affordable and equitable access to lenacapavir. This approach aims to ensure that more people can benefit from this groundbreaking innovation right from the outset.
